Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 177

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 177
---
 disclosures.

In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) which expands annual
and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses
and segment profit or loss. ASU 2023-07 also requires entities with a single reportable segment to provide all segment disclosures under
ASC 280, including the new required disclosures under the ASU. We adopted ASU 2023-07 on a retrospective basis for the 2024 annual period,
and for interim periods beginning in 2025. The impact is limited to our financial statement disclosures, which are presented in Note 2
to the accompanying consolidated condensed financial statements.

34

In December 2023, the FASB issued ASU 2023-09,
Income Taxes (ASC 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) which requires disaggregated information
about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective
for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact that ASU 2023-09
will have on our financial statement disclosures.

In November 2024, the FASB issued ASU 2024-03,
Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income
Statement Expenses (“ASU 2024-03”), which applies to all public business entities that file financial statements with
the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information
about certain income statement expense line items. The new standard is effective for fiscal years beginning after December 15, 2026, with
early adoption permitted. We are currently evaluating the impact that ASU 2024-03 will have on our financial statement disclosures.

ITEM 3. Quantitative and Qualitative Disclosures
about Market Risk

As a smaller reporting company as defined by Rule
12b-2 of the Exchange Act of 1934, as amended and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations
and therefore are not required to provide the information requested by this